European Journal of Cancer

Analysis and presentation of cost data from randomised trials
pp. 1-1(1)
Author: Barber J.

Cost-effectiveness analysis of Paclitaxel and Cisplatinum versus Cyclophosphamide and Cisplatin as first-line therapy in advanced ovarian cancer - a European perspective
pp. 1-1(1)
Authors: Berger K.; Szucs T.

Applying time-dependent outcomes and Markov modelling to the economic evaluation of cytotoxics: A case study of Paclitaxel and Topotecan in the treatment of advanced ovarian cancer
pp. 1-2(2)
Authors: Bethel L.; Stanley A.

Cost-effectiveness of Irinotecan (CPT-11) and best estimated chemotherapy regimen in patients with metastatic colorectal cancer after failure of 5fluorouracil (5FU) containing regimen: Results based on a phase III trial
pp. 2-2(1)
Authors: Blijham G.; Schmitt C.; Aussage P.; Henry-Launois B.; Jolain B.; Herait P.

Economic evaluation of chemotherapy with Mitoxantrone plus Prednisone for symptomatic hormone resistant prostate cancer based on a Canadian randomised trial with palliative endpoints
pp. 2-2(1)
Authors: Bloomfield D.; Krahn M.; Willan A.; Tannock I.

Costs of care in a randomised trial of early hospital discharge after surgery for breast cancer
pp. 2-3(2)
Authors: Bonnema J.; van Wersch A.; van Geel A.; Pruyn J.; Schmitz P.; Uyl-de Groot C.; Wiggers T.

Country-specific adaptations of a cost-utility decision model comparing chemotherapy in recurrent metastatic breast cancer
pp. 3-3(1)
Authors: Brown R.; Hutton J.

Economic implications of hepatic arterial infusion chemotherapy in the treatment of nonresectable colorectal liver metastases
pp. 3-3(1)
Authors: Durand-Zaleskski I.; Roche B.; Buyse M.; Carlson R.; O'Connell M.; Rougier P.; Chang A.; Sondak V.; Kemeny M.; Allen-Mersh T.; Fagniez P.-L.; Le Bourgeois J.-P.; Piedbois P.

The cost of radiotherapy at an Ontario regional cancer centre
pp. 4-4(1)
Authors: Earle C.; Coyle D.; Smith A.; Agboola O.; Evans W.

Integrating patients' preferences in therapeutic decisions in cancer: Development of a decision board
pp. 4-4(1)
Authors: Ferdjaoui N.; Carrere M.; Bremond A.; Charavel M.; Fervers B.; Grattadour A.; Voog E.; Philip T.

Evaluation of relative costs of the cytostatic agents Tomudex(R) and 5-Fluorouracil plus Leucovorin as treatments for advanced colorectal cancer
pp. 4-5(2)
Authors: Groener M.; van Ineveld B.; Byttebier G.; Rutten F.

Results of an economic evaluation of a RCT of routine follow-up after primary treatment for breast cancer: A comparison of primary care vs specialist care
pp. 5-5(1)
Authors: Grunfeld E.; Gray A.; Mant D.; Coyle D.; Yudkin P.; Fitzpatrick R.; Vessey M.

Economics of the MRC Colorectal Working Party CR06 Trial
pp. 5-5(1)
Authors: Hale J.; Cohen D.; Maughan T.

Diagnostic Imaging in Cancer. The Economics of PET
pp. 5-6(2)
Authors: James M.; Hunt K.

Use of the EuroQoL among patients receiving radiochemotherapy for pancreatic cancer: Psychometrical tests and quality adjusted survival analysis
pp. 6-6(1)
Authors: Konig H.; Stratmann D.

Cost-effectiveness and quality of life evaluation, in the context of current practice, of antiemetics used for the control of chemotherapy induced emesis
pp. 6-7(2)
Authors: Lachaine J.; Laurier C.; Langleben A.; Vaillant L.

Costs and quality of life in metastatic colorectal cancer
pp. 7-7(1)
Authors: Launois R.; Reboul-Marty J.; de Monts M.

Optimization of peripheral blood stem cell collection (PBSC) by leukapheresis: a case of interaction between economic and clinical assessment of an innovation
pp. 7-7(1)
Authors: Le Corroller A.; Moatti J.; Chabannon C.; Faucher C.; Blaise D.; Fortanier D.; Ladaique P.; Blache B.; Novakovitch G.; Maraninchi D.

Quality of life assessments of patients with pancreatic cancer receiving MTA (LY231514, a multi-targeted antifolate)
pp. 8-8(1)
Authors: Liepa A.; Picus J.; Blanke C.; John W.; Clark J.; Schulman L.; Burris H.; Thornton D.; Loehrer P.

Discordance between physicians' estimations and breast cancer patients' self-assessment of side-effects of chemotherapy: An issue for measuring the impact of anticancer treatments
pp. 8-8(1)
Authors: Macquart-Moulin G.; Genre D.; Bouscary M.; Camerlo J.; Cappiello M.; Gravis G.; Maraninchi D.; Moatti J.; Viens P.

Macro-financing mechanisms, micro-innovation incentives and resources (re-) allocation in anticancer treatments : experience from a French cancer institute
pp. 8-9(2)
Author: Paraponaris A.

Economic evaluation of Amifostine in the treatment of small cell lung cancer (SCLC)
pp. 9-9(1)
Authors: Poulter K.; Shevlin P.; Johnson P.; Davies L.

Elicitation of preferences and patients participation in the decision making process
pp. 9-9(1)
Authors: Protiere C.; Genre D.; Cowen D.; Gravis G.; Camerlo J.; Alzieu C.; Bertucci F.; Maraninchi D.; Moatti J.; Viens P.

Costs and quality of life in metastatic breast cancer
pp. 9-10(2)
Authors: Reboul-Marty J.; Launois R.

A Systematic Review of Health Benefit Valuation in Economic Evaluations in Cancer
pp. 10-10(1)
Authors: Sculpher M.; Brown J.

Assessing the relative costs of standard open surgery and laparoscopic surgery in colorectal cancer in a randomised controlled trial
pp. 10-11(2)
Authors: Stead M.; Brown J.; Franks P.; Bosanquet N.; Guillou P.; Quirke P.; Jayne D.; Webb A.

Anastrozole 1mg provides a cost-effective survival benefit, compared with megestrol acetate, for patients treated for advanced breast cancer
pp. 11-11(1)
Authors: Thompson E.; Drummond M.; Howell A.; Jonat W.; Brown J.

Evaluation of economic consequences of general prostate cancer screening program in France: A decision model
pp. 11-11(1)
Authors: Thoral F.; Niddam K.; Cuzin C.; Charvet-Protat S.

Institutional structure, financing mechanisms and heterogeneity in health care supply: Experience from 1078 breast cancer patients in a French region
pp. 12-12(1)
Authors: Tonnaire G.; Paraponaris A.; Chanut C.; Sambuc R.

Cost-effectiveness of faecal occult blood screening for colorectal cancer: results of the Nottingham trial
pp. 12-12(1)
Authors: Whynes D.; Walker A.; Neilson A.

The cost of breast cancer: Implications for screening
pp. 12-13(2)
Authors: Wolstenholme J.; Whynes D.

The cost of cervical cancer: Implications for screening
pp. 13-13(1)
Authors: Wolstenholme J.; Whynes D.

Determining the importance of specific symptoms for the economic evaluation of advanced prostate cancer therapies
pp. 13-13(1)
Authors: Yabroff K.; Barofsky I.; Pearson A.; Rothman M.

Resource implications of paclitaxel/cisplatinum versus cyclophosphamide/cisplatinum in the treatment of advanced ovarian cancer
pp. 15-15(1)
Authors: Adriaenssen I.; Piccart M.; Roy J.; Hoctin B.G.

Costs of inappropriate hospital use in cancer and non-cancer patients in a tertiary university hospital
pp. 15-15(1)
Authors: Akhan A.S.; Hayran M.; Sain G.; Unal S.

Cost-analysis of cervical cancer screening in the Flemish Region: The spontaneous versus the organised approach
pp. 15-16(2)
Authors: Arbyn M.; Van Oyen H.

Cost-effectiveness of radionuclide bone scanning to rule out asymptomatic bone metastases in clinically operable non-small cell lung cancer
pp. 16-16(1)
Authors: Arican A.; Dincol D.; Samur M.; Demirkazlk A.; Sencan O.; Akbulut H.; Karaoguz H.; Cay F.; Icli F.

Teicoplanin or vancomycin in febrile neutropenic children with cancer: A randomized cost effectiveness study
pp. 16-16(1)
Authors: Auperin A.; Capelli C.; Benhamou E.; Pinna A.; Peeters P.; Atlani C.; Hartmann O.

Medico-economic evaluation of the cost of education in a cancer center
pp. 16-17(2)
Authors: Bercez C.; Michel J.; Bonneterre M.; Morel S.; Bonneterre J.

Economic evaluation of patients (pts) with lymphomas enrolled into phase II-III clinical trials (ct) in an oncology centre
pp. 17-17(1)
Authors: Bordonaro R.; Serraino D.; Miele M.; Ritossa D.; Morassut S.; De Paoli P.; De Marco L.; Cimitan M.; Pinto A.; Carbone A.; Zagonel V.

The impact of changing the reimbursement system for radiotherapy in Catalonia
pp. 17-17(1)
Authors: Borras J.; Espinas J.; Peris M.; Constante C.

Cost-quality of life study in inflammatory breast cancer (IBC) out patients receiving high dose intensity chemotherapy with RH-GCSF and stem cell support (PEGASE 2)
pp. 17-18(2)
Authors: ''Economic/Quality of Life/Intensive Therapy'' Group of the National French; Viens P.; Bouscary M.; Palangie T.; Roche H.; Fabbro M.; Janvier M.; Delozier T.; Macquart-Moulin G.; Moatti J.

Economic evaluation of adjuvant treatment for early breast cancer
pp. 18-18(1)
Authors: Brown J.; Kamon J.; Eldabi T.; Paul R.

Summary recommendations from the conference on purchasing oncology services: Methods & models in the marketplace
pp. 18-18(1)
Authors: Cangialose C.; Ballard D.; Hayes R.; Blair A.; Borchardt J.; Ades T.; Liberati A.

Decision model for the cost of using opioids to treat cancer pain
pp. 18-19(2)
Authors: Guest J.; Hart W.; Fallon M.; Cookson R.

Comparison of the cost of managing constipation in cancer patients receiving oral morphine or transdermal fentanyl
pp. 19-19(1)
Authors: Guest J.; Munrol V.; Cookson R.

Cost of serious adverse drug reactions related to anti-cancer chemotherapy
pp. 19-19(1)
Authors: Couffignal A.; Lapeyre-Mestre M.; Bonhomme C.; Bugat R.; Montastruc J.

Methods for conducting economic analysis of the long-term management of breast cancer: Description of two current Canadian studies
pp. 19-20(2)
Authors: Coyle D.; Grunfeld E.; Levine M.; Evans W.

Multi-centre economic evaluation of chart in the treatment of patients with head and neck cancer and carcinoma of the bronchus: Lessons for future studies
pp. 20-20(1)
Authors: Coyle D.; Drummond M.

An economic comparison of inpatient versus outpatient treatment of febrile neutropenia in a pediatric oncology ward
pp. 20-21(2)
Authors: Crott R.; Dhooge C.; Benoit Y.; Laureys G.

Hospital costs of intensive chemotherapy followed by peripheral stem cell reinfusion
pp. 21-21(1)
Authors: Donnet-Descartes V.; Cometta A.; Kovacsovics T.; Wasserfallen J.

Pharmacoeconomic evaluation of Etoposide Phosphate vs. Etoposide in small cell lung cancer: A European (five-country) study
pp. 21-21(1)
Authors: Doyle J.; Dhanani S.; Lappas P.; Sinha N.; Martin C.; Arikian S.

Opportunities to reduce the cost of care for breast cancer (BC) in Canada
pp. 21-22(2)
Authors: Evans W.; Le Petit C.; Will B.; Berthelot J.; Tomiak E.; Verma S.

President Reagan's colon cancer legacy: the long term public health and economic benefits of a discrete event
pp. 22-22(1)
Authors: Fabricant R.; Fintor L.

Revealed preferences in clinical trials
pp. 22-22(1)
Author: Felder S.

An early economic evaluation of a therapeutic innovation in the field of cancerology: the case of the peripheral blood progenitor cells (PBPC) allogeneic transplantation
pp. 23-23(1)
Authors: Fortanier C.; Faucher C.; Tonnaire G.; Protiere C.; Le Corollier A.; Blaise D.; Moatti J.

The cost of the radiotherapy (RT): a Piedmont regional experience
pp. 23-23(1)
Authors: Gabriele P.; Ozzello F.; Sinistrero G.; Baiotto B.; Rotta P.; Pasquino M.; Negri G.

Resource use in the management of patients with Dukes' C colon carcinoma
pp. 23-24(2)
Author: Glendenning A.

Comparing the costs and cost-effectiveness of new chemotherapy regimens for treating non-small cell lung cancer (NSCLC)
pp. 24-24(1)
Authors: Gralla R.; Grusenmeyer P.

Cost minimization analysis of treatment of T1N0 glottic squamous cell carcinomas: Comparison between radiotherapy, laser microsurgery and partial laryngectomy
pp. 24-24(1)
Authors: Gregoire V.; Hamoir M.; Bussels J.; Closon M.; Eeckhoudt L.; Counoy H.; Rosier J.; Scalliet P.

Cost considerations in alternatives to inpatient care in the administration of chemotherapy and supportive care
pp. 24-25(2)
Authors: Grusenmeyer P.; Gralla R.; Trapani M.; Bateman N.

Economic evaluation of the use of prophylactic Clodronate to treat multiple myeloma
pp. 25-25(1)
Authors: Bruce N.; McCloskey E.; Kanis J.; Guest J.

Economic assessment of Clodronate in the preventive treatment of bone resorption in patients with metastatic breast cancer
pp. 25-25(1)
Authors: Guignard E.; Dardenne J.; Pelc A.

The relative economics of screening for colorectal cancer, breast cancer and cervical cancer
pp. 25-26(2)
Author: Gyrd-Hansen D.

The impact of cancer on premature death in Japan
pp. 26-26(1)
Authors: Hamashima C.; Hasegawa T.

The benefit of stabilization under chemotherapy in metastatic colorectal cancer patients: A French prospective study
pp. 26-27(2)
Authors: Henry-Launois B.; Aussage P.; Becouarn Y.; de Monts M.

Economic analysis of adjuvant Interferon-ALFA 2B (IFN) in high risk melanoma using projections from ECOG (E) 1684
pp. 27-27(1)
Authors: Hillner B.; Kirkwood J.; Atkins M.; Johnson E.; Smith T.

Use of economic models in an evolving drug evaluation strategy: An example in treatment of metastatic breast cancer
pp. 27-27(1)
Authors: Hutton J.; Brown R.

Economic effect of multiple fraction per day with acceleration (MF) in extended radiotherapy of patients with Hodgkin's disease (HD)
pp. 27-27(1)
Authors: Ilyin N.; L.I. Koritova L.

Pharmacoeconomic analysis of the antagonists 5-HT3 in the control of chemotherapy-induced emesis in children
pp. 28-28(1)
Authors: Jimenez Monteagudo M.; Carrera J.; Leon P.; Gimeno J.; Sierrasesumaga L.

Issues in developing an economic evaluation of an innovative cancer control program for the medically underserved
pp. 28-28(1)
Authors: Jones W.; Rodgers K.; Nixon D.; Hoskins D.; Wilson D.; Lackland D.

The cost of radiation treatment at two Greek radiotherapy centres
pp. 28-29(2)
Authors: Kardamakis D.; Salvaras N.; Dimopoulos J.

Economic Analysis of cancer treatments taking QoL into consideration
pp. 29-29(1)
Authors: Koinuma N.; Ito M.

Economic analysis of patients with breast cancer in a health maintenance organization
pp. 29-29(1)
Authors: Konski A.; Wilder L.; LeSage J.

Cost-efficacy evaluation of fludarabine phosphate in the treatment of chronic lymhocytic leukemia refractory to other therapies
pp. 29-30(2)
Authors: Laplante S.; Grenier J.

Quality of life assessments of patients with non-small cell lung cancer receiving Gemcitabine (Gemzar^TM) and Cisplatin
pp. 30-30(1)
Authors: Anton A.; Carrato A.; Gonzalez-Larriba J.; Vadel C.; Masutti B.; Montalar J.; Aranda E.; Liepa A.

Cost-quality of life study in advanced no metastatic breast cancer patients treated by a high dose chemotherapy with sequential reinfusion of blood stem cells
pp. 30-30(1)
Authors: Macquart-Moulin G.; Bouscary M.; Protiere C.; Genre D.; Maraninchi D.; Moatti J.; Viens P.

Development of a pharmacoeconomics service in a provincial oncology centre
pp. 31-31(1)
Authors: Malfair T.S.; Chow L.

Economies of scale and technological efficiency in state-wide cancer detection programs
pp. 31-31(1)
Authors: Mansley E.; May D.; Dunet D.

Efficiency of follow-up strategies after radical surgery for colonic cancer (RSCC). A decision analysis
pp. 31-32(2)
Authors: Michel P.; Merle V.; Paillot B.; Mauillon J.; Duerotte P.; Czernichow P.

A review of the pharmacoeconomic research on Gemcitabine (Gemzar^TM) is the treatment of advanced non-small cell lung cancer
pp. 32-32(1)
Authors: Minshall M.; Liepa A.

Management of lung cancer - a comparison of management strategies, outcomes and resource utilisation in specialist and non specialist centres
pp. 32-32(1)
Authors: Stroner P.; Cull A.; Dunnett J.

Economic evaluation of endocrine therapies for post-menopausal metastatic breast cancer
pp. 32-33(2)
Authors: Sorensen S.; Munro V.; Hutton J.

Information asymmetries and strategic consequences of a prospective payment-like regulation in health care: Evidence from the twenty French cancer institutes
pp. 33-33(1)
Author: Paraponaris A.

Determinants of treatment costs for stage III and IV colon cancer patients in Latvia. Evaluation of oral treatment with Ftorafur and Ftorafur/Leucovorin
pp. 33-33(1)
Authors: Plate S.; Berzins J.

A quality-adjusted survival (Q-TWIST) analysis of EORTC trial 30853 comparing maximal androgen blockade (MAB) with orchiectomy in patients with metastatic prostate cancer
pp. 33-34(2)
Authors: Rosendahl K.; Curran D.; Kiebert G.; Cole B.; Weeks J.; Denis L.; Hall R.

Economic impact of the harmonization of practice using guidelines: The example of breast cancer surveillance
pp. 34-34(1)
Authors: Roy T.; Mille D.; Carrere M.; Ray I.; Fervers B.; Farsi F.; Philip T.

Brain stem tumors treatment: Economical cost
pp. 34-34(1)
Authors: de Sanchez T.J.; Hernandez J.; Gallego S.; Sabado C.; Gros L.; Rodriguez M.; de Kelety A.; Quiles A.

A model of patients' preferences for chemotherapy outcomes in advanced colorectal cancer: Do gains in survival justify the toxicity?
pp. 34-35(2)
Authors: Schmitt C.; Henry-Launois B.; Jolain B.; Cavallo M.; Mantovani L.

Economic burden of colon cancer in the US using a national database
pp. 35-35(1)
Author: Seifeldin R.

Medico-economic evaluation of colorectal cancer screening programs: The Nord/Pas-de-Calais/Picardie experience
pp. 35-36(2)
Authors: Selke B.; Dervaux B.; Lebrun T.; Sailly J.

Medico-economic evaluation of breast cancer adjuvant treatment
pp. 36-36(1)
Authors: Bercez C.; Lenne X.; Selke B.; Bonneterre M.; Sailly J.; Lebrun T.; Bonneterre J.

Cost and outcome in UK palliative care services
pp. 36-36(1)
Authors: Small N.; Ahmedzai S.; Coyle D.; Rice N.; Ashworth A.; Hennessy S.; Jenkins-Clark S.; Mannion R.; Mallett K.

Adaptation of pharmacoeconomic software
pp. 37-37(1)
Author: Malfair Taylor S.

Cost/effectiveness assessment of cytogenetic and molecular biology analysis for acute leukemia's prognosis
pp. 37-37(1)
Authors: Tonnaire G.; Gabert J.; Lafage M.; Sainty D.; Maraninchi D.; Moatti J.

Statistical inference and sample sizes for cost-effectiveness analyses
pp. 37-37(1)
Author: van den Hout W.

Resource utilisation in intensive chemotherapy, autologous versus allogeneic bone marrow transplantation in acute myeloid leukemia
pp. 37-38(2)
Authors: Zittoun R.; Mandelli F.; Suciu S.; Keating S.; Dardenne M.; Berneman Z.; De Witte T.; Willemze R.; Van Der Heyden M.

Economic evaluation of high dose chemotherapy for breast cancer patients
pp. 38-38(1)
Authors: van Enckevort P.; TenVergert E.; de Vries E.; Rodenhuis S.

Using appropriate comparators in economic evaluations: An exercise for Belgium
pp. 38-38(1)
Authors: Van Tigggelen O.; Storme G.; Torfs K.; Van den Berge D.; De Coene N.

Cost effectiveness analysis of two strategies of treatment for stage III non surgical non small cell lung cancer
pp. 39-39(1)
Authors: Vergnenegre A.; Daures J.

Cost identification of PAV versus ICE treatment in SCLC
pp. 39-39(1)
Authors: Rollier P.; Perey L.; Bauer J.; Leyvraz S.; Wasserfallen J.

Cost effectiveness of FDG-PET in the evaluation of solitary pulmonary nodules
pp. 39-39(1)
Authors: Weber W.; Bulow H.; Romer W.; Prauer H.; Gambhir S.; Schwaiger M.

The costs of pancreatic cancer: Methodology of costing rare cancers
pp. 40-40(1)
Author: Wilson L.